IFT81: A Potential Drug Target for Pro-Inflammatory Diseases (G28981)

Target Name: IFT81

NCBI ID: G28981

IFT81

IFT81: A Potential Drug Target for Pro-Inflammatory Diseases

IFT81 (Interleukin-8-1) is a cytokine that is produced by various cell types in the body. It is a pro-inflammatory cytokine that plays a crucial role in the immune response and has been implicated in a number of diseases, including cancer , autoimmune disorders, and chronic obstructive pulmonary disease (COPD).

IFT81 has been identified as a potential drug target (or biomarker) due to its ability to regulate the immune response and its potential to intervene in a variety of diseases. In this article, we will explore the biology and function of IFT81, as well as its potential as a drug target.

Biogenesis and function
IFT81 is produced by a variety of cell types in the body, including macrophages, dendritic cells, and epithelial cells. It is a cytokine that is involved in the immune response and has been shown to play a role in the regulation of inflammation, cell proliferation , and apoptosis.

IFT81 has been shown to have a variety of functions in the body. For example, it has been shown to regulate the immune response by promoting the production of pro-inflammatory cytokines and suppressing the production of anti-inflammatory cytokines. IFT81 has also been shown to promote the growth and survival of cancer cells, and to contribute to the development and progression of certain diseases, including cancer.

Drug targeting
IFT81 has been identified as a potential drug target due to its ability to regulate the immune response and its potential to intervene in a variety of diseases. One way to target IFT81 is through the use of small molecules, such as inhibitors of the production of IFT81 or inhibitors of its function. These small molecules would be delivered directly to the cells that produce IFT81, and would be designed to disrupt its ability to regulate the immune response or promote the growth and survival of cancer cells.

Another approach to targeting IFT81 is through the use of monoclonal antibodies (MCAs), which are laboratory-produced antibodies that are designed to recognize and bind to specific molecules in the body. MCAs can be used to target IFT81 directly and prevent it from functioning.

IFT81 has also been shown to be a potential biomarker for a number of diseases. For example, it has been shown to be elevated in the blood of people with cancer, and has been used as a marker for the efficacy of certain cancer treatments. It has also been shown to be elevated in the blood of people with autoimmune disorders, such as rheumatoid arthritis and lupus.

Conclusion
IFT81 is a cytokine that is produced by various cell types in the body and has been implicated in a number of diseases, including cancer and autoimmune disorders. Its potential as a drug target (or biomarker) has been identified due to its ability to regulate the immune response and its potential to intervene in a variety of diseases. Further research is needed to fully understand the biology and function of IFT81, as well as its potential as a drug target.

Protein Name: Intraflagellar Transport 81

Functions: Component of the intraflagellar transport (IFT) complex B: together with IFT74, forms a tubulin-binding module that specifically mediates transport of tubulin within the cilium. Binds tubulin via its CH (calponin-homology)-like region (PubMed:23990561). Required for ciliogenesis (PubMed:27666822, PubMed:23990561). Required for proper regulation of SHH signaling (PubMed:27666822). Plays an important role during spermatogenesis by modulating the assembly and elongation of the sperm flagella (By similarity)

The "IFT81 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFT81 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets